Compare LODE & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | HELP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 233.0M |
| IPO Year | 2004 | N/A |
| Metric | LODE | HELP |
|---|---|---|
| Price | $4.19 | $6.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.00 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 05-11-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $1,582.85 | N/A |
| Revenue Next Year | $246.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $3.76 |
| 52 Week High | $4.98 | $8.55 |
| Indicator | LODE | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 64.99 |
| Support Level | $3.54 | $5.76 |
| Resistance Level | $4.18 | $6.26 |
| Average True Range (ATR) | 0.32 | 0.44 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 23.77 | 70.98 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.